...
首页> 外文期刊>American Journal of Cancer Research >ZNF217: the cerberus who fails to guard the gateway to lethal malignancy
【24h】

ZNF217: the cerberus who fails to guard the gateway to lethal malignancy

机译:ZNF217:未能保护致命恶性肿瘤的网关的Cerberus

获取原文
           

摘要

The aberrant expression of the zinc finger protein 217 (ZNF217) promotes multiple malignant phenotypes, such as replicative immortality, maintenance of proliferation, malignant heterogeneity, metastasis, and cell death resistance, via diverse mechanisms, including transcriptional activation, mRNA N 6 -methyladenosine (m 6 A) regulation, and protein interactions. The induction of these cellular processes by ZNF217 leads to therapeutic resistance and patients’ poor outcomes. However, few ZNF217 related clinical applications or trials, have been reported. Moreover, looming observations about ZNF217 roles in m 6 A regulation and cancer immune response triggered significant attention while lacking critical evidence. Thus, in this review, we revisit the literature about ZNF217 and emphasize its importance as a prognostic biomarker for early prevention and as a therapeutic target.
机译:锌指蛋白217(ZnF217)的异常表达促进多种恶性表型,例如复制不朽,增殖,恶性异质性,转移和细胞死亡率和细胞死亡抗性,包括转录激活,mRNA n 6 - 甲基喹啉( M 6 A)调节和蛋白质相互作用。 通过ZnF217诱导这些细胞过程导致治疗性抗性和患者的差。 然而,已经报道了很少有ZNF217相关的临床应用或试验。 此外,对M 6中的ZnF217作用的迫近观察调节和癌症免疫应答在缺乏关键证据时引发了重大关注。 因此,在本综述中,我们重新审视了ZNF217的文献,并强调其重视预防预防和治疗靶标的预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号